Source: Annual Congress 2004 - Exploring new basic aspects of treatment of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. S. Campos, I. Teixeira, M. B. G. Oliveira, D. G. Xisto, L. M. Lima, E. J. Barreiro, N. R. D. Rodrigues, T. Mauad, W. A. Zin, P. R. M. Rocco (Rio de Janeiro, São Paulo, Brazil). Effects of a selective phosphodiesterase IV and V inhibitor in a murine model of chronic asthma. Eur Respir J 2004; 24: Suppl. 48, 866

Member's Comments

No comment yet.

Related content which might interest you: Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001 Effect of phosphodiesterase 4 (PDE-4) inhibitor – rolipram with or without co-administration of dexamethasone on experimental asthma - guinea pig model Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004 Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Effect of a pan-JAK inhibitor pyridone 6 on airway responses in murine asthma model Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010 Effect of a thrombin inhibitor on murine bronchial asthma Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009 The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001 Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 NIK-616,a new type of selective PDE IV inhibitor with reduced emetic activity Source: Eur Respir J 2002; 20: Suppl. 38, 618s Year: 2002 Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 Terapeutic potential of different phosphodiesterase inhibitors in a model of acute lung injury Source: Eur Respir J 2004; 24: Suppl. 48, 264s Year: 2004 Effects of phosphodiesterase 3/4 inhibition on matrixmetalloproteinases 2 and 9 in chronic experimental pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 435s Year: 2004 Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury Source: Eur Respir J 2003; 22: 20-27 Year: 2003 Anti-asthmatic effects of losartan, a blocker of angiotensin II type 1 receptor, in a rat model of allergic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003 Effect of phosphodiesterase 4B inhibitor GSK256066 on leukocyte/endothelium interactions from chronic obstructive pulmonary disease: an in vitro study. Source: International Congress 2017 – Management of COPD Year: 2017 Effects of combination treatments with the PPAR β/δ agonist GW0742 and the phosphodiesterase type V inhibitor, sildenafil on markers of pulmonary hypertension in hypoxic rats Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 The effect of an oral phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in primate asthma models Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001